Comparer des méthodes

	Conception expérimentale à sujet unique et à aveuglement simple	Essai contrôlé randomisé simple aveugle
Domaine	Plans d'expériences	Plans d'expériences
Famille	Process / pipeline	Process / pipeline
Année d'origine	1970s–1984 (consolidated)	1948 (formalized); single-blind variant established in mid-20th century clinical trial methodology
Auteur d'origine	Barlow & Hersen (single-subject methodology); blinding conventions from clinical trial tradition	Bradford Hill and colleagues (MRC streptomycin trial, 1948); blinding conventions codified in CONSORT guidelines
Type	Controlled experimental design variant	Experimental design — blinded randomized trial
Source fondatrice	Barlow, D. H., & Hersen, M. (1984). Single case experimental designs: Strategies for studying behavior change (2nd ed.). Pergamon Press. ISBN: 978-0080302378	Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332.
Alias	single-blind N-of-1 design, SB-SSED, single-blind within-subject design, single-blind single-case experimental design	single-masked RCT, single-blind RCT, single-blind trial, SB-RCT
Apparentées	6	5
Résumé	A single-blind single-subject experimental design (SB-SSED) applies a single-blind protocol to an N-of-1 experiment: one individual participant is studied intensively across alternating or sequential phases, and either the participant or the assessor — but not both — is kept unaware of the current treatment condition. This design combines the idiographic power of single-subject methodology with a structured blinding control to reduce performance or assessment bias, and is common in applied behavior analysis, clinical psychology, and rehabilitation research.	A single-blind randomized controlled trial (SB-RCT) is a rigorous experimental design in which participants are randomly assigned to treatment or control conditions while remaining unaware of which condition they have received. Investigators, outcome assessors, and data analysts are not blinded. By masking participants, the design eliminates placebo and nocebo response biases on the participant side, while preserving investigator flexibility to administer and monitor the intervention.